open surgeries (366). Additionally, two retrospective analyses showed improved disease-free and overall survival for patients with pancreatic cancer and reduced morbidity during surgery for patients with liver cancer who underwent minimally invasive surgeries compared to those who received open surgeries (365,367). Yet another report from an early-stage clinical trial showed that a selected subset of patients with breast cancer who responded remarkably well to neoadjuvant chemotherapy could potentially forgo surgery without risking tumor recurrence (368). Recent studies have also identified subsets of patients who could skip surgery altogether without compromising outcomes. In a clinical trial, women who had early-stage breast cancer with defined clinical characteristics had equally good overall survival whether they received radiotherapy delivered to the lymph nodes in their underarms (axillary radiotherapy), or an invasive surgical procedure to remove these lymph nodes (axillary lymph node dissection) (369). Notably, axillary lymph node dissection is associated with a significantly higher rate of morbidity, particularly lymphedema, which causes swelling Newly FDA-approved Anticancer Agents: August 1, 2022-July 31, 2023 TYPE OF TREATMENT GENERIC NAME TRADE NAME WHAT IS IT? APPROVED FOR? Surgery, Chemotherapy, Radiotherapy flotufolastat fluorine-18 Posluma Imaging agent Certain type of prostate cancer pafolacianine* Cytalux Imaging agent Certain type of lung cancer Molecularly Targeted Therapy adagrasib§ Krazati Cell-signaling inhibitor Certain type of lung cancer fam-trastuzumab deruxtecan-nxki§ Enhertu Antibody–drug conjugate Certain type of lung cancer* selpercatinib Retevmo Cell-signaling inhibitor Solid tumors carrying certain type of genetic mutation* mirvetuximab soravtansine-gynx§ Elahere Antibody–drug conjugate Certain type of ovarian cancer elacestrant Orserdu Antihormone Certain type of breast cancer futibatinib Lytgobi Cell-signaling inhibitor Certain type of bile duct cancer dabrafenib + trametinib Tafinlar + Mekinist Cell-signaling inhibitors Certain type of glioma* tucatinib + trastuzumab Tukysa + Herceptin Cell-signaling inhibitors Certain type of colorectal cancer* olutasidenib§ Rezlidhia Epigenome modifying agent Certain type of leukemia quizartinib§ Vanflyta Cell-signaling inhibitor Certain type of leukemia pemigatinib Pemazyre Cell-signaling inhibitor Certain types of blood cancer* pirtobrutinib Jaypirca Cell-signaling inhibitor Certain types of lymphoma zanubrutinib Brukinsa Cell-signaling inhibitor Certain types of lymphoma* talazoparib Talzenna DNA repair inhibitor Certain type of prostate cancer* Immunotherapy tremelimumab + durvalumab Imjudo + Imfinzi Immune checkpoint inhibitors Certain type of liver and lung cancers retifanlimab-dlwr Zynyz Immune checkpoint inhibitor Certain type of skin cancer durvalumab Imfinzi Immune checkpoint inhibitor Certain type of gallbladder cancer* atezolizumab Tecentriq Immune checkpoint inhibitor Alveolar soft part sarcoma* nadofaragene firadenovec-vncg Adstiladrin Gene therapy Certain type of bladder cancer teclistamab-cqyv Tecvayli Bispecific antibody Multiple myeloma mosunetuzumab-axgb Lunsumio Bispecific antibody Certain type of lymphoma epcoritamab-bysp Epkinly Bispecific antibody Certain type of lymphoma glofitamab-gxbm Columvi Bispecific antibody Certain type of lymphoma *New cancer type approved 2022-2023 §Requires a companion diagnostic TABLE 3 Advancing the Frontiers of Cancer Science and Medicine AACR Cancer Progress Report 2023 77
RkJQdWJsaXNoZXIy NTkzMzk=